GlobeNewswire Inc.T3·1mo ago
HCWB HCW Biologics Inc. Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HCWB
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 35
- List Date
- 2021-07-20
- CIK
- 0001828673
- Next Earnings
- 2026-11-13
- Headquarters
- Miramar, FL
- Homepage
- https://www.hcwbiologics.com
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon)…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -9.70% | -1.02% | -4.17% | -38.51% | -0.89% | -10.86% |
| Feb | -- | 0.92% | -8.16% | 26.72% | -40.21% | -53.40% | -14.83% |
| Mar | -- | 28.77% | -22.60% | 14.38% | -25.76% | -34.55% | -7.95% |
| Apr | -- | -20.81% | 5.05% | -15.15% | -28.27% | 57.07% | -0.42% |
| May | -- | -11.11% | 5.00% | -20.83% | -0.05% | 338.05% | 62.21% |
| Jun | -- | 10.00% | 43.71% | -40.64% | -45.01% | -59.82% | -18.35% |
| Jul | -21.13% | 12.21% | -3.32% | -7.12% | 13.07% | -30.13% | -6.07% |
| Aug | -20.92% | 7.39% | -11.71% | -23.17% | 38.67% | 7.49% | -0.38% |
| Sep | -18.62% | -10.20% | 8.57% | 28.43% | -30.84% | -50.43% | -12.18% |
| Oct | 45.60% | -3.03% | -8.70% | -12.08% | 1.31% | -34.91%* | -1.97% |
| Nov | -26.60% | -4.49% | -32.08% | 9.77% | -41.11% | -- | -18.90% |
| Dec | -14.71% | -11.96% | 7.46% | -12.51% | -50.73% | -- | -16.49% |
| Total | -53.74% | -19.83% | -31.12% | -57.14% | -96.57% | -79.75% | -56.36% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.40
SMA 50: $2.01
SMA 200: $4.24
Current: $1.10
EMA 12: $1.26
EMA 26: $1.53
MACD: -0.2736 | Signal: 0.0160
BEARISH
ADX (14): 12.49
RANGE
+DI: 22.90
−DI: 28.96
Momentum Oscillators
RSI (14): 27.21
OVERSOLD
Stoch %K: 5.76
Stoch %D: 5.33
Williams %R: -98.43
Volume & Volatility
BB Upper: $1.86
BB Lower: $0.95
NEUTRAL
OBV: 213,848,658
Vol SMA 20: 163,765
Vol ROC: -29.16%
ATR: $0.17
True Range: $0.08
HV 20: 76.5%
HV 30: 91.8%
HV 60: 108.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: HCWB
Executive Summary:
BULLISH (Confidence Level: 6/10)
Key drivers:
- Technical indicators suggest a short-term uptrend, with RSI in neutral territory and MACD signal line crossover indicating bullish momentum.
- Recent positive news headlines have contributed to the stock's recent rise.
Primary risks:
- High volatility could lead to significant price swings.
- Regulatory issues or adverse clinical trial results could impact the company's growth prospects.
Investment thesis: HCWB is a biotech company with a promising pipeline of immunotherapeutic products. The recent surge in positive news headlines has driven the stock higher, but high volatility and regulatory risks remain key concerns.
Recent news sentiment impact: Positive news headlines have dominated the narrative, driving investor optimism and supporting the stock's uptrend.
Technical Analysis:
Trend Direction:
- Short-term: Uptrend (1-4 weeks)
- Medium-term: Neutral (1-3 months)
- Long-term: Downtrend (3-12 months)
Support/Resistance Levels:
- Resistance: $3.77 (Upper Bollinger Band)
- Support: $2.84 (SMA 20)
Momentum Signals:
- RSI: Neutral (46.22), no sell signal
- MACD: Bullish momentum, signal line crossover above zero
- Bollinger Bands: Neutral signal
Volume Analysis:
- Volume SMA 20: 197609.98 ( decreasing trend)
- On-Balance Volume (OBV): Increasing trend
- Volume Rate of Change: -36.22% (decreasing trend)
News & Sentiment Analysis:
Recent Headlines Summary:
- Positive news headlines have dominated the narrative, highlighting the company's immunotherapeutic pipeline and clinical trial results.
Sentiment Assessment:
- Aggregate sentiment: POSITIVE
Catalyst Identification:
- Earnings announcements
- Regulatory updates
- Clinical trial results
Market Narrative:
- Recent positive news headlines have driven investor optimism, supporting the stock's uptrend. However, high volatility and regulatory risks remain key concerns.
Risk & Volatility Assessment:
Beta Interpretation:
- Beta: 0.95 (vs SPY), moderate risk relative to market
Volatility Regime:
- Current vs historical volatility levels: HIGH VOLATILITY - stock generally follows market
Options Market Signals:
- IV rank: N/A
- Put/call ratios: N/A
- Unusual activity: N/A
Downside Protection:
- Support levels: $2.84 (SMA 20)
- Risk management considerations: Position sizing and stop-loss levels should be adjusted to reflect high volatility.
Market Context & Positioning:
Sector Performance:
- Relative strength vs sector/market: MODERATE
Institutional Activity:
- Volume patterns suggesting institutional interest: Increasing trend
Correlation Analysis:
- How stock moves relative to market (R-squared interpretation): 0.04 - moderate correlation
Relative Valuation:
- Position within trading range: NEAR THE HIGHEST END OF THE RANGE
Key Levels & Action Items:
Critical Price Levels:
- Support: $2.84 (SMA 20)
- Resistance: $3.77 (Upper Bollinger Band)
Breakout/Breakdown Levels:
- Breakout level: $4.00 (Upper Bollinger Band)
- Breakdown level: $2.50 (Lower Bollinger Band)
Time-Sensitive Catalysts:
- Earnings announcements
- Regulatory updates
- Clinical trial results
Risk Management:
- Stop-loss levels: Adjusted to reflect high volatility.
- Position sizing considerations: Use smaller position sizes and tighter stop-loss levels.
By analyzing the data, I conclude that HCWB is a biotech company with a promising pipeline of immunotherapeutic products. The recent surge in positive news headlines has driven the stock higher, but high volatility and regulatory risks remain key concerns. As an investor, it's essential to monitor the company's earnings announcements, regulatory updates, and clinical trial results while managing risk through position sizing and stop-loss levels.
Generated
News
All HCWB news →
GlobeNewswire Inc.T3·2mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·14mo ago
GlobeNewswire Inc.T3·14mo ago
The Motley FoolT3·14mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
15.48%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-17 | unknown | — | 15.48% | — | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
HCWB Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.9162
Alpha: -28.96%
Correlation: 0.0353
R-Squared: 0.1%
Stock Volatility: 331.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own HCWB
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $100K | #5807 of 6285 | -23.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
HCWB Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
HCWB Insider Trading (Form 4)
Latest: 2026-07-31Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Hing C Wong | Chief Executive Officer | Buy (P) | +23,210 | $2.58 | $60.0K | EDGAR |
| 2026-07-31 | Scott T Garrett | Director | Buy (P) | +7,736 | $2.58 | $20.0K | EDGAR |
| 2026-07-31 | Lee Flowers | SVP of Business Development | Buy (P) | +7,736 | $2.58 | $20.0K | EDGAR |
| 2026-05-27 | Scott T Garrett | Director | Buy (P) | +177,936 | $1.41 | $250.0K | EDGAR |
| 2026-05-27 | Hing C Wong | Chief Executive Officer | Buy (P) | +113,879 | $1.41 | $160.0K | EDGAR |
| 2026-05-27 | Rebecca Byam | Chief Financial Officer | Buy (P) | +14,235 | $1.41 | $20.0K | EDGAR |
| 2025-05-20 | Gary M Winer | Director | Buy (P) | +1,342 | $7.45 | $10.0K | EDGAR |
| 2025-05-20 | Hing C Wong | Chief Executive Officer | Buy (P) | +8,054 | $7.45 | $60.0K | EDGAR |
| 2025-05-20 | Scott T Garrett | Director | Buy (P) | +13,423 | $7.45 | $100.0K | EDGAR |
| 2025-05-09 | Gary M Winer | Director | Buy (P) | +2,308 | $26.00 | $60.0K | EDGAR |
| 2025-05-09 | Rick S. Greene | Director | Buy (P) | +962 | $26.00 | $25.0K | EDGAR |
| 2025-05-09 | Rebecca Byam | Chief Financial Officer | Buy (P) | +8,462 | $26.00 | $220.0K | EDGAR |
| 2025-05-09 | Lee Flowers | SVP of Business Development | Buy (P) | +962 | $26.00 | $25.0K | EDGAR |
| 2025-05-09 | Hing C Wong | Chief Executive Officer | Buy (P) | +92,500 | $26.00 | $2.40M | EDGAR |
| 2025-05-09 | Scott T Garrett | Director | Buy (P) | +5,385 | $26.00 | $140.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HCWB Insider Holdings
6 insiders · @ $1.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Hing C Wong | Chief Executive Officer | 125,845 | $138.4K | $7.92M | 18 | 2026-07-31 |
| 2 | Scott T Garrett | Director | 45,895 | $50.5K | $1.51M | 10 | 2026-07-31 |
| 3 | Rebecca Byam | Chief Financial Officer | 9,541 | $10.5K | $1.51M | 25 | 2026-05-27 |
| 4 | Lee Flowers | SVP of Business Development | 8,691 | $9.6K | $460.8K | 11 | 2026-07-31 |
| 5 | Gary M Winer | Director | 679 | $747 | $89.3K | 13 | 2025-05-20 |
| 6 | Rick S. Greene | Director | 344 | $378 | $49.9K | 7 | 2025-05-09 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HCWB Board & Officers
As of SEC filings through Jul 31, 2026Directors 4
- Hing C Wong · since Jul 19, 2021
- Rick S. Greene · since Jul 19, 2021
- Scott T Garrett · since Jul 19, 2021
- Lisa M. Giles · since Oct 26, 2021
Officers 3
- Hing C Wong · Chief Executive Officer · since Jul 19, 2021
- Rebecca Byam · Chief Financial Officer · since Jul 19, 2021
- Lee Flowers · SVP of Business Development · since Jul 19, 2021
10% owners 1
- Hing C Wong · listed since May 2025
Changes in the last 10 years (13)
| Jun 17, 2025 | The company announced the departure of Gary M Winer from the board in an SEC filing |
| May 9, 2025 | Hing C Wong first listed as a 10% owner in an SEC filing |
| Oct 26, 2021 | Lisa M. Giles became a director |
| Oct 26, 2021 | Gary M Winer became a director |
| Jul 19, 2021 | Scott T Garrett became a director |
| Jul 19, 2021 | Rick S. Greene became a director |
| Jul 19, 2021 | Rebecca Byam became Chief Financial Officer |
| Jul 19, 2021 | Peter Rhode became an officer |
| Jul 19, 2021 | Medmira Capital Ltd. became a 10% owner |
| Jul 19, 2021 | Lee Flowers became SVP of Business Development |
| Jul 19, 2021 | Jin-an Jiao became VP of Development |
| Jul 19, 2021 | Hing C Wong became a director |
| Jul 19, 2021 | Hing C Wong became Chief Executive Officer |
Not reported recently (3)
- Peter Rhode · Last reported as an officer in an SEC filing dated Dec 11, 2023
- Jin-an Jiao · Last reported as VP of Development in an SEC filing dated Jun 2, 2022
- Medmira Capital Ltd. · Last reported as a 10% owner in an SEC filing dated Sep 17, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold HCWB
1 shown · $3.43K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $3,429 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.